Full-Time

Scientist – Rare Disease Biology

Posted on 9/9/2026

Deadline 9/16/26
Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$123.1k - $166.5k/yr

+ Annual bonus + Stock-based long-term incentives

South San Francisco, CA, USA

In Person

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Data Analysis
Biochemical Assays

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A doctorate degree, or a master's degree and 2 years of relevant scientific research experience, or a bachelor's degree and 4 years of relevant scientific research experience.
  • Expertise in one or more areas relevant to fibroblast biology, stromal cell biology, tissue remodeling, fibrosis, extracellular matrix biology, inflammation, or fibro-inflammatory disease.
  • Experience investigating cellular and molecular mechanisms that drive tissue inflammation, remodeling, and pathological structural changes.
  • Demonstrated expertise in designing and executing cell-based, molecular, and biochemical assays to interrogate complex disease biology and therapeutic hypotheses.
  • Hands-on experience with primary human cells, fibroblast systems, tissue-derived cultures, organoids, or other advanced in vitro/ex vivo disease models.
  • Strong understanding of biological pathways involved in fibroblast activation, extracellular matrix regulation, fibrosis, wound healing, inflammation, and tissue remodeling.
  • Experience applying multi-omics data or other data-rich approaches to characterize cellular phenotypes and disease mechanisms.
  • Strong quantitative and data-analysis skills, with demonstrated ability to interpret complex biological datasets and translate findings into testable hypotheses.
  • Experience integrating experimental data with human genetics, omics, clinical data, and scientific literature to generate mechanistic and translational insights.
  • Ability to combine experimental and computational approaches to solve complex biological questions and support target evaluation.
  • Ability to work effectively in collaborative, multidisciplinary, and matrixed research environments.
Responsibilities
  • Design, execute, analyze, and interpret in vitro and ex vivo studies to investigate disease mechanisms and evaluate therapeutic hypotheses.
  • Generate high-quality, reproducible experimental data to support target identification, validation, and progression of rare disease research programs.
  • Investigate biological mechanisms relevant to Thyroid Eye Disease, including immune dysregulation, fibroblast activation, inflammatory signaling, extracellular matrix regulation, and tissue remodeling.
  • Integrate experimental findings with scientific literature, human genetics, clinical observations, and multi-omic datasets to develop mechanistic insights and inform scientific decision-making.
  • Develop and implement innovative experimental approaches that enhance scientific rigor, efficiency, and translational relevance.
  • Collaborate closely with disease biologists, computational scientists, translational researchers, and other partner functions within multidisciplinary research teams.
  • Contribute data-driven insights and recommendations to scientific discussions, target reviews, program strategy, and portfolio evaluations.
  • Build productive relationships with internal and external collaborators, including academic investigators, foundations, contract research organizations, and scientific experts, as appropriate.
  • Communicate scientific findings, interpretations, and recommendations effectively to project teams, governance forums, and departmental audiences.
  • Maintain accurate experimental documentation and contribute to organizational knowledge sharing.
  • Foster a culture of scientific curiosity, collaboration, continuous learning, and operational excellence.
Desired Qualifications
  • Familiarity with artificial intelligence-enabled scientific tools, computational workflows, image analysis, automation, or advanced data analytics.
  • Scientific curiosity and demonstrated ability to rapidly learn new disease areas, biological systems, technologies, and analytical approaches.
  • Excellent written and verbal communication skills, with the ability to communicate complex scientific concepts clearly to diverse audiences.
  • Ability to balance scientific rigor, urgency, and adaptability in a dynamic research environment.
  • Demonstrated commitment to teamwork, knowledge sharing, and continuous improvement.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $38.2 billion-$39.4 billion.
  • Repatha sales jumped 37% to $953 million in Q2 2026, with U.S. prescriptions up 50%.
  • MariTide advanced through multiple Phase 3 studies in 2026, supporting a 2027 obesity catalyst.

What critics are saying

  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy cash cow.
  • FDA proposed withdrawing Tavneos in April 2026, signaling regulatory risk from integrity and efficacy issues.
  • Olpasiran now faces Novartis pelacarsen failure scrutiny; a negative 2028 OCEAN(a) readout would crush Lp(a) upside.

What makes Amgen unique

  • Repatha, Evenity, and Uplizna diversify Amgen beyond one blockbuster, per August 2026 sales.
  • MariTide targets quarterly or eight-week dosing, unlike Lilly and Novo Nordisk weekly injections.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-enabled drug discovery globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.

Yahoo Finance
Sep 7th, 2026
Amgen's $437 olpasiran bet faces higher bar after Novartis Lp(a) drug fails Phase 3 trial

Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.